Project Grant K08HL177161
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $730,070 to the University of Arizona to develop and test a novel class of hybrid polyplex nanoparticles (P22-F1 PBAE/PEI/PEG) that can specifically target and deliver DNA plasmids to lung capillary endothelial cells. The goal is to stimulate lung regeneration and decrease pulmonary hypertension in mouse and rat models of bronchopulmonary dysplasia, a severe...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $106,391 to the University of Colorado-Denver to investigate the role of developmental dysanapsis in lung development over the lifespan in an experimental bronchopulmonary dysplasia (BPD) model. The research aims to determine whether intra-amniotic endotoxin causes persistent dysanaptic growth of the airways, distal parenchyma, and vasculature in BPD, and...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,559,308 to examine the impact of severe pre-eclampsia on heart function in diverse racial groups of women. The project will evaluate heart function at delivery and at 6- and 12-months postpartum, as well as characterize the cardiomyopathic genetic profile of the participants. A sub-award of undisclosed amount has been issued to...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- This Cooperative Agreement award, totaling $740,915, was granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The overall goal of the award is to elucidate novel mechanisms linking placental ischemia and maternal systemic, cerebral, and renal dysfunction in preeclampsia, and to identify potential therapeutic targets. The University of Mississippi Medical Center, the award recipient, has developed and...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $166,395 to Columbia University to conduct a 5-year research project on the impact of hyperoxia (excess oxygen) on the function of respiratory progenitor cells in neonates. The project aims to develop a better understanding of the mechanisms by which post-natal lung development occurs in the face of injurious agents like oxygen...
- This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the role of the hedgehog pathway and primary cilia axis in human lung alveologenesis and diseases such as bronchopulmonary dysplasia (BPD). The $156,168 grant awarded to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center will fund a 2-year study examining the cellular and molecular...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $586,021 to The Medical College of Wisconsin, Inc. to establish patient-reported outcome measures that refine neonatal risk stratification and identify barriers to post-discharge specialty care for preterm infants with bronchopulmonary dysplasia (BPD). The goal is to identify hospital-to-home transition strategies that reduce post-prematurity respiratory...
- This federal Project Grant award of $806,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Yale University aims to gain insights into maternal endothelial dysfunction and develop novel therapeutic strategies with a focus on plasminogen activator inhibitor 1 (PAI1) as a drug target for preeclampsia. The research seeks to understand how PAI1 contributes to the pathophysiology of preeclampsia, a leading cause of maternal and neonatal...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $773,868 to Baylor College of Medicine to elucidate the mechanisms regulating inflammation and the role of regulatory T cells (Tregs) in the development of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH). The award aims to use well-established murine models and human biosamples to examine the mechanistic and therapeutic potential of Tregs in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $166,752 to Boston Medical Center Corporation to develop models of placenta-driven developmental lung injury in human preeclampsia. The 5-year project aims to characterize the influence of human preeclampsia on fetal lung development. Specifically, the research will: 1) Identify preeclampsia-specific placental proteins in the fetal circulation that contribute to lung developmental injury pathways; and 2) Develop an in vitro model to evaluate the effects of these placental proteins on alveolar epithelium and pulmonary vasculature. This work is expected to advance understanding of the antenatal determinants of bronchopulmonary dysplasia, a significant cause of short- and long-term health issues in preterm infants.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $166.8k | 8/18/25 |